The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor

Molecular and Cellular Endocrinology

Volumn 351, Issue 2, 2012, Pages 249-263

  Kasina, Sathish ^a   Macoska, Jill A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Androgen; Androgen receptor; CXCL12; CXCR4; Proliferation; Prostate

Indexed keywords

ANDROGEN RECEPTOR; CHEMOKINE RECEPTOR CXCR4; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; STEROID RECEPTOR COACTIVATOR 1;

ARTICLE; BIOACCUMULATION; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TRANSPORT; REGULATOR GENE; WILD TYPE;

ANDROSTADIENES; BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL12; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIGANDS; MALE; NITRILES; NUCLEAR RECEPTOR COACTIVATOR 1; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, CXCR4; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION;

EID: 84857141616     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.12.015     Document Type: Article

References (85)

1. Alen P., Claessens F., Verhoeven G., Rombauts W., Peeters B. The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol. Cell. Biol. 1999, 19:6085-6097.
2. Araki S., Omori Y., Lyn D., Singh R.K., Meinbach D.M., Sandman Y., Lokeshwar V.B., Lokeshwar B.L. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007, 67:6854-6862.
3. Arnold J.T., Gray N.E., Jacobowitz K., Viswanathan L., Cheung P.W., McFann K.K., Le H., Blackman M.R. Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells. J. Steroid Biochem. Mol. Biol. 2008, 111:240-246.
4. Attardi B.J., Burgenson J., Hild S.A., Reel J.R. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol. Cell. Endocrinol. 2004, 222:121-132.
5. Begley L., Monteleon C., Shah R.B., Macdonald J.W., Macoska J.A. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell. 2005, 4:291-298.
6. Begley L.A., Kasina S., MacDonald J., Macoska J.A. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008, 43:194-199.
7. Begley L.A., MacDonald J.W., Day M.L., Macoska J.A. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J. Biol. Chem. 2007, 282:26767-26774.
8. Berrevoets C.A., Doesburg P., Steketee K., Trapman J., Brinkmann A.O. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol. Endocrinol. 1998, 12:1172-1183.
9. Bevan C.L., Hoare S., Claessens F., Heery D.M., Parker M.G. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol. Cell. Biol. 1999, 19:8383-8392.
10. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., Springer T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382:829-833.
11. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E., Wright K., Howard M.C., Schall T.J. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203:2201-2213.
12. Burnstein K.L., Cidlowski J.A. Multiple mechanisms for regulation of steroid hormone action. J. Cell. Biochem. 1993, 51:130-134.
13. Chan L., O'Malley B.W. Mechanism of action of the sex steroid hormones (first of three parts). N. Engl. J. Med. 1976, 294:1322-1328. (review).
14. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2002, 10:33-39.
15. Craft N., Chhor C., Tran C., Belldegrun A., DeKernion J., Witte O.N., Said J., Reiter R.E., Sawyers C.L. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999, 59:5030-5036.
16. Cronauer M.V., Schulz W.A., Burchardt T., Anastasiadis A.G., de la Taille A., Ackermann R., Burchardt M. The AR in hormone-refractory prostate cancer: relevance of different mechanisms of AR signaling (Review). Int. J. Oncol. 2003, 23:1095-1102.
17. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. AR activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994, 54:5474-5478.
18. Culig Z., Hobisch A., Hittmair A., Peterziel H., Cato A.C., Bartsch G., Klocker H. Expression, structure, and function of AR in advanced prostatic carcinoma. Prostate 1998, 35:63-70.
19. Culig Z., Steiner H., Bartsch G., Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J. Cell. Biochem. 2005, 95:497-505.
20. Daaka Y. G proteins in cancer: the prostate cancer paradigm. Sci. STKE 2004, (216):re2. (review).
21. Dai J., Shen R., Sumitomo M., Stahl R., Navarro D., Gershengorn M.C., Nanus D.M. Synergistic activation of the AR by bombesin and low-dose androgen. Clin. Cancer Res. 2002, 8:2399-2405.
22. D'Antonio J.M., Vander Griend D.J., Antony L., Ndikuyeze G., Dalrymple S.L., Koochekpour S., Isaacs J.T. Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One 2010, 5(7):e11475.
23. Debes J.D., Tindall D.J. The role of androgens and the AR in prostate cancer. Cancer Lett. 2002, 187:1-7.
24. Denmeade S.R., Sokoll L.J., Dalrymple S., Rosen D.M., Gady A.M., Bruzek D., Ricklis R.M., Isaacs J.T. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003, 54:249-257.
25. Ding X.F., Anderson C.M., Ma H., Hong H., Uht R.M., Kushner P.J., Stallcup M.R. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol. Endocrinol. 1998, 12:302-313.
26. Donzella G.A., Schols D., Lin S.W., Esté J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., Moore J.P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 1998, 4:72-77.
27. Edwards J., Bartlett J.M. The androgen receptor and signal-transduction pathways in hormone refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. B.J.U. Int. 2005, 95:1327-1335. (review).
28. Esquenet M., Swinnen J.V., Heyns W., Verhoeven G. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids. J. Steroid Biochem. Mol. Biol. 1997, 62:391-399.
29. Fong C.J., Sherwood E.R., Braun E.J., Berg L.A., Lee C., Kozlowski J.M. Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions. Prostate 1992, 21:121-131.
30. Frigo D.E., Sherk A.B., Wittmann B.M., Norris J.D., Wang Q., Joseph J.D., Toner A.P., Brown M., McDonnell D.P. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol. Endocrinol. 2009, 23:1385-1396.
31. Furr B.J., Valcaccia B., Curry B., Woodburn J.R., Chesterson G., Tucker H. ICI 176, 334: a novel non-steroidal, peripherally selective antiandrogen. J. Endocrinol. 1987, 113:R7-R9.
32. Geller J. Prolonging survival in metastatic prostate cancer: the case for adrenal androgens - overview and summary of therapeutic controversies in prostatic cancer. J. Clin. Endocrinol. Metab. 1995, 80:1074-1078. (review).
33. Ghosh P.M., Malik S.N., Bedolla R.G., Wang Y., Mikhailova M., Prihoda T.J., Troyer D.A., Kreisberg J.I. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr. Relat. Cancer 2005, 12:119-134.
34. Gregory C.W., Fei X., Ponguta L.A., He B., Bill H.M., French F.S., Wilson E.M. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem. 2004, 279:7119-7130.
35. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., Wilson E.M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61:4315-4319.
36. Ham J., Thomson A., Needham M., Webb P., Parker M. Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus. Nucleic Acids Res. 1988, 16:5263-5276.
37. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the AR. Cancer Res. 1998, 58:4640-4645.
38. Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 1980, 37:115-132.
39. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
40. Jia L., Shen H.C., Wantroba M., Khalid O., Liang G., Wang Q., Gentzschein E., Pinski J.K., Stanczyk F.Z., Jones P.A., Coetzee G.A. Locus-wide chromatin remodeling and enhanced AR-mediated transcription in recurrent prostate tumor cells. Mol. Cell. Biol. 2006, 26:7331-7341.
41. Karpf A.R., Bai S., James S.R., Mohler J.L., Wilson E.M. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol. Cancer Res. 2009, 7:523-535.
42. Kasina S., Scherle P.A., Hall C.L., Macoska J.A. ADAM-mediated amphiregulin shedding and EGFR transactivation. Cell. Prolif. 2009, 42:799-812.
43. Klein K.A., Reiter R.E., Redula J., Moradi H., Zhu X.L., Brothman A.R., Lamb D.J., Marcelli M., Belldegrun A., Witte O.N., Sawyers C.L. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 1997, 3:402-408.
44. Korenchuk S., Lehr J.E., MClean L., Lee Y.G., Whitney S., Vessella R., Lin D.L., Pienta K.J. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001, 15:163-168.
45. Kreisberg J.I., Malik S.N., Prihoda T.J., Bedolla R.G., Troyer D.A., Kreisberg S., Ghosh P.M. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004, 64:5232-5236.
46. Lamont K.R., Tindall D.J. Androgen regulation of gene expression. Adv. Cancer Res. 2010, 107:137-162. (review).
47. Lee L.F., Guan J., Qiu Y., Kung H.J. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol. Cell. Biol. 2001, 21:8385-8397.
48. Lee L.F., Louie M.C., Desai S.J., Yang J., Chen H.W., Evans C.P., Kung H.J. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004, 23:2197-2205.
49. Lee S.O., Chun J.Y., Nadiminty N., Lou W., Feng S., Gao A.C. Interleukin-4 activates AR through CBP/p300. Prostate 2009, 69:126-132.
50. Lee S.O., Lou W., Hou M., Onate S.A., Gao A.C. Interleukin-4 enhances prostate-specific antigen expression by activation of the AR and Akt pathway. Oncogene 2003, 22:7981-7988.
51. Lee S.O., Lou W., Nadiminty N., Lin X., Gao A.C. Requirement for NF-(kappa)B in interleukin-4-induced AR activation in prostate cancer cells. Prostate 2005, 64:160-167.
52. Lee S.O., Pinder E., Chun J.Y., Lou W., Sun M., Gao A.C. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008, 68:85-91.
53. Lin B., Ferguson C., White J.T., Wang S., Vessella R., True L.D., Hood L., Nelson P.S. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999, 59:4180-4184.
54. Lin H.K., Yeh S., Kang H.Y., Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA 2001, 98:7200-7205.
55. Linja M.J., Savinainen K.J., Saramäki O.R., Tammela T.L., Vessella R.L., Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61:3550-3555.
56. Lopez G.N., Turck C.W., Schaufele F., Stallcup M.R., Kushner P.J. Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J. Biol. Chem. 2001, 276:22177-22182.
57. Lu Y., Zhang J., Dai J., Dehne L.A., Mizokami A., Yao Z., Keller E.T. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin. Exp. Metastasis 2004, 21:399-408.
58. Ma H., Hong H., Huang S.M., Irvine R.A., Webb P., Kushner P.J., Coetzee G.A., Stallcup M.R. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol. Cell. Biol. 1999, 19:6164-6173.
59. MacManus C.F., Pettigrew J., Seaton A., Wilson C., Maxwell P.J., Berlingeri S., Purcell C., McGurk M., Johnston P.G., Waugh D.J. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol. Cancer Res. 2007, 5:737-748.
60. Malik S.N., Brattain M., Ghosh P.M., Troyer D.A., Prihoda T., Bedolla R., Kreisberg J.I. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin. Cancer Res. 2002, 8:1168-1171.
61. Malinowska K., Neuwirt H., Cavarretta I.T., Bektic J., Steiner H., Dietrich H., Moser P.L., Fuchs D., Hobisch A., Culig Z. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the AR. Endocr. Relat. Cancer 2009, 16:155-169.
62. McCall P., Gemmell L.K., Mukherjee R., Bartlett J.M., Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br. J. Cancer. 2008, 98:1094-1101.
63. Mohler J.L., Titus M.A., Bai S., Kennerley B.J., Lih F.B., Tomer K.B., Wilson E.M. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 2011, 71:1486-1496.
64. Mohler J.L. Castration-recurrent prostate cancer is not androgen-independent. Adv. Exp. Med. Biol. 2008, 617:223-234. (review).
65. Oñate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357.
66. Ortí E., Bodwell J.E., Munck A. Phosphorylation of steroid hormone receptors. Endocr. Rev. 1992, 13:105-128.
67. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12:1665-1671.
68. Riegman P.H., Vlietstra R.J., van der Korput J.A., Brinkmann A.O., Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 1991, 5:1921-1930.
69. Rot A., von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann. Rev. Immunol. 2004, 22:891-928.
70. Rowan B.G., Garrison N., Weigel N.L., O'Malley B.W. 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol. Cell. Biol. 2000, 20:8720-8730.
71. Rowan B.G., Weigel N.L., O'Malley B.W. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 2000, 275:4475-4483.
72. Scher H.I., Buchanan G., Gerald W., Butler L.M., Tilley W.D. Targeting the AR: improving outcomes for castration-resistant prostate cancer. Endocr. Relat. Cancer 2004, 11:459-476.
73. Seaton A., Scullin P., Maxwell P.J., Wilson C., Pettigrew J., Gallagher R., O'Sullivan J.M., Johnston P.G., Waugh D.J. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of AR expression and activation. Carcinogenesis 2008, 29:1148-1156.
74. Shi Y., Brands F.H., Chatterjee S., Feng A.C., Groshen S., Schewe J., Lieskovsky G., Cote R.J. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J. Urol. 2001, 166:1514-1519.
75. Sramkoski R.M., Pretlow T.G., Giaconia J.M., Pretlow T.P., Schwartz S., Sy M.S., Marengo S.R., Rhim J.S., Zhang D., Jacobberger J.W. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell. Dev. Biol. Anim. 1999, 35:403-409.
76. Steketee K., Timmerman L., Ziel-van der Made A.C., Doesburg P., Brinkmann A.O., Trapman J. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int. J. Cancer 2002, 100:309-317.
77. Takizawa I., Nishiyama T., Hara N., Hoshii T., Ishizaki F., Miyashiro Y., Takahashi K. Trilostane, an inhibitor of 3β-hydroxysteroid dehydrogenase, has an agonistic activity on androgen receptor in human prostate cancer cells. Cancer Lett. 2010, 297:226-230.
78. Tan J., Sharief Y., Hamil K.G., Gregory C.W., Zang D.Y., Sar M., Gumerlock P.H., deVere White R.W., Pretlow T.G., Harris S.E., Wilson E.M., Mohler J.L., French F.S. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 1997, 11:450-459.
79. Taplin M.E., Balk S.P. AR: a key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem. 2004, 91:483-490.
80. Tørring N., Vinter-Jensen L., Sørensen F.B., Flyvbjerg A., Nexø E. Systemic treatment with epidermal growth factor but not insulin-like growth factor I decreases the involution of the prostate in castrated rats. Urol. Res. 2000, 28:75-81.
81. Ueda T., Mawji N.R., Bruchovsky N., Sadar M.D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 2002, 277:38087-38094.
82. van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003, 57:205-225.
83. Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 1990, 173:534-540.
84. Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H., Hung M.C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000, 60:6841-6845.
85. Yeh S., Lin H.K., Kang H.Y., Thin T.H., Lin M.F., Chang C. From HER2/Neu signal cascade to AR and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 1999, 96:5458-5463.